New Free Clinical Trials Search Tool for Mesothelioma Launches

A new, free online search tool dedicated exclusively to mesothelioma clinical trials has launched on mesotheliomahelp.org, offering patients, physicians, and researchers a focused resource to find and share trials specific to mesothelioma and its subtypes. The platform, which is the first of its kind devoted solely to mesothelioma, combines detailed disease-specific filters with geographic search capability and an easy process for clinicians and investigators to submit trials for inclusion.

The tool’s design focuses on two core needs: helping patients and families find relevant trials quickly and giving doctors and researchers a simple way to make their trials visible to a larger, targeted audience. Users can search by type of cancer (for example, pleural mesothelioma, peritoneal mesothelioma, tunica vaginalis mesothelioma, or pericardial mesothelioma) and then narrow results by geographic location, from state-level searches down to city or zip-code proximity options. The combination of disease specificity and location-based searching is meant to cut through the noise of broader clinical-trial registries and accelerate connections between patients and trials that are realistically accessible.

Search Clinical Trials

Once a patient or caregiver builds a shortlist of promising trials, the site emphasizes the practical next step: patients are encouraged to take the list to their treating physicians to discuss feasibility and eligibility. The goal is to put the patient in the driver’s seat but with a solid reminder that treatment should be a collaboration between patient/family and physician. Having a curated list of clinical trials in hand at their appointment can help streamline the conversation and rapidly assess whether a trial’s inclusion criteria apply to that patient based on data from previous phases of that trial, the patient’s disease stage, previous treatment and response, and wellbeing.

The platform also invites doctors and researchers to submit their trials for inclusion.

While clinical trials are experimental and not yet proven treatments, in a rare cancer like mesothelioma with few available treatments with limited effectiveness, they are a way to try something different, especially when other things haven’t worked or stopped working. But that doesn’t mean that no data exists for these novel treatments. In fact, the opposite is often true. The new treatments tend to already have data in other cancers based and if the study is a Phase 3 clinical trial, then it also has data signals for mesothelioma specifically.

Clinical trials proceed in phases — from early, small safety studies (Phase I) to larger tests of effectiveness (Phase II and III) and post-approval follow-ups (Phase IV). For patients with mesothelioma, particularly those with advanced or treatment-resistant disease, clinical trials can provide access to the latest therapies before they are widely available, including targeted therapies, immunotherapies, and novel combination strategies. Participation can offer potential clinical benefits such as tumor shrinkage or prolonged disease control; at the same time, trials also carry risks and may not be effective for every participant. Importantly, clinical trials generate the evidence that advances cancer treatment for all patients in the future.

The site’s mesothelioma-only focus is the feature that sets it apart. Whereas registries that catalog trials across all cancers can be comprehensive, they are not always user-friendly for users without a medical background. By concentrating on one disease group, the search tool can present deeper, more relevant filtering options and educational material tailored to mesothelioma patients’ unique needs.

For investigators and research sites, the platform also offers visibility benefits. Submitting a trial to the search tool increases the chance that eligible patients and referring physicians who are specifically searching for mesothelioma options will find the trial. That improved visibility can accelerate enrollment, reduce screening times, and help trials reach target accrual sooner.

As clinical research continues to expand and treatments for mesothelioma evolve rapidly, tools that connect patients and clinicians to appropriate studies are increasingly valuable. This mesothelioma-dedicated, free, searchable database with disease-type and location filters and a direct submission process for investigators aims to be a practical bridge between the clinical-research community and the people who may benefit from participation. Patients and clinicians interested in exploring the new search tool can visit mesotheliomahelp.org to begin searching, learn how to submit trials, and find resources to guide conversations with treating physicians about clinical-trial options.

What Experts Revealed at iMig 2025 About the Next Wave of Mesothelioma Therapies

The 2025 gathering of the International Mesothelioma Interest Group (iMig) offered a powerful snapshot of where treatment for mesothelioma is heading, with a mix of clinical debate, scientific breakthroughs, and evolving therapeutic strategies. Several recurring themes emerged, notably around the role of surgery, advances in targeted therapies, and the expanding use of systemic treatments.

Surgery Under Scrutiny, but Still an Option in the United States

One of the central conversations revolved around the findings of the MARS2 trial, a UK-based multicenter study that randomized pleural mesothelioma patients (after two cycles of chemo) to either continue chemotherapy alone or undergo surgery followed by further chemo. The trial concluded that surgery provided no clear survival benefit.

These results shook long-held assumptions in the field and stimulated a strong re-evaluation of when surgery should be used. Experienced surgeons at the conference argued that the trial may not reflect optimal, real-world surgical practice citing concerns about patient selection and higher mortality in the surgical group.

Still, some high-volume mesothelioma centers (especially those handling 25+ cases per year) maintain that surgery can remain part of a broader multimodal treatment plan. In other words: though surgery may not cure, it could help extend life when combined with modern systemic therapies performed at experienced centers.

Because current systemic treatments yield a median survival around 18–24 months, combining refined surgical strategies with systemic therapy remains a goal. Trials incorporating immunotherapy either before or after surgery were spotlighted as especially promising.

A New Target: The Hippo Pathway and TEAD Inhibitors

Beyond surgical debates, researchers pointed to new molecular avenues such as the dysregulated Hippo pathway, which is disrupted in roughly 60% of mesothelioma cases. This makes it an attractive target for drug development.

Agents like Vivace VT3989 (a TEAD palmitoylation inhibitor) and IAG933 (which interferes with TEAD-YAP/TAZ interactions) are currently under development or in regulatory review for advanced solid tumors, including mesothelioma.

Preclinical data presented at iMig suggest that combining TEAD inhibition with immunotherapy may enhance immune cell infiltration into tumors, potentially improving effectiveness. However, the presence of Hippo pathway abnormalities alone isn’t yet a reliable predictor of who benefits.

This line of research could open new doors for patients, especially those whose tumors aren’t well served by existing chemo or immunotherapy regimens.

Systemic Therapies

Attendees reviewed the current arsenal of systemic treatments and looked ahead to future combinations. For patients who relapse, single-agent immunotherapy remains an option: for example, nivolumab has demonstrated improved progression-free survival compared with placebo, though overall survival gains are modest.

Other agents, such as pembrolizumab, show response rates in relapsed disease similar to older chemo drugs like gemcitabine or vinorelbine.

More importantly, several clinical trials are now exploring combinations intended to improve outcomes. For instance:

The BEAT‑meso trial is testing standard chemo plus a blend of an immunotherapy agent and a VEGF inhibitor.
The IND 227 trial compared chemo alone to chemo plus pembrolizumab, revealing particular benefit for non-epithelioid subtypes such as sarcomatoid or biphasic mesothelioma.
Other trials include MIST 4 trial (atezolizumab + bevacizumab after prior chemo), RAMES trial (gemcitabine with ramucirumab vs. placebo), and investigations of antibody-drug conjugates like anetumab ravtansine, either alone or combined with immunotherapy.

New Hope for Aggressive Subtypes: Sarcomatoid and Biphasic Mesothelioma

Patients with sarcomatoid or mostly sarcomatoid tumors have long faced grim prognoses, given that those subtypes respond poorly to standard treatments. Results from studies in recent years, though, have shown growing evidence that immunotherapy can meet a critical need here.

One particularly important development: in nonepithelioid pleural mesothelioma, the combination of chemotherapy with pegargiminase significantly improved outcomes in the ATOMIC‑meso trial. According to the data discussed, pegargiminase caused a modest increase in overall survival (about 1.6 months), but more strikingly, quadrupled 3-year survival compared to chemotherapy alone. The drug works by starving tumor cells of arginine, a nutrient certain mesothelioma cells can’t produce on their own, which weakens their growth ability.

While immune-based regimens remain powerful, they can also lead to unpredictable side effects; in such cases, pegargiminase represents a promising alternative or addition for individuals who may not tolerate immunotherapy or who are not candidates for immunotherapy.

What’s Next

Discussions at iMig underscored a balance between realism and optimism. On one hand, the field recognizes the many hurdles left to overcome as mesothelioma remains difficult to treat, and no single approach is a silver bullet. On the other, there is clear momentum toward better patient outcomes, built on improved surgical techniques, deeper biological understanding, novel drug targets, and smarter combination therapies.

The conference reaffirmed that the future of mesothelioma care likely lies in personalization: matching treatment strategies (surgery, chemo, immunotherapy, targeted agents) to tumor biology, disease subtype, and patient condition. With ongoing clinical trials and evolving research, there is growing hope that the standard of care will continue to shift giving patients more options and, ultimately, much more time.

Could adding a COVID-19 vaccination to immunotherapy lead to better outcomes for mesothelioma?

A new study in Nature has sparked excitement among cancer researchers, revealing that immune therapies like nivolumab (Opdivo) and ipilimumab (Yervoy) may be more effective when paired with an mRNA-based COVID-19 vaccine. These immune checkpoint inhibitors work by releasing the natural restraints on immune cells, allowing them to recognize and attack cancer more efficiently.

The research highlights a surprising connection between mRNA vaccines, originally designed for COVID-19, and the performance of immune checkpoint inhibitors (ICIs). Scientists observed that administering an mRNA vaccine encoding the SARS-CoV-2 spike protein triggered strong immune activation, including a rise in type I interferons and stimulation of innate immune cells. This immune boost enhanced the priming of CD8+ T cells which act as key players in attacking tumor cells.

In animal studies, combining the vaccine with ICIs led to far greater tumor shrinkage than either therapy used alone. Remarkably, this effect was also seen in so-called “cold” tumors, which are usually resistant to immunotherapy.

The human data mirrored these results. Patients with advanced non-small cell lung cancer (NSCLC) or melanoma who received an mRNA COVID-19 vaccine within 100 days of starting ICI treatment showed notably improved overall survival compared to those who had not been vaccinated during that window.

Tumor samples from these patients also revealed higher PD-L1 expression after vaccination, suggesting that the vaccine may help make tumors more visible to the immune system and more responsive to checkpoint inhibition.

These findings suggest a new way of thinking about vaccines as not just as tools for preventing infection, but as potential enhancers of cancer immunotherapy. While the study did not specifically focus on mesothelioma, the results are of great interest to mesothelioma researchers, as immune checkpoint inhibitors have already offered improved outcomes over traditional therapies, though their overall benefit remains limited.

Veterans Day 2025: Asbestos Exposure and Mesothelioma Among Veterans

For much of the 20th century, asbestos was used throughout the U.S. military branches for its heat resistance and insulating properties. It could most often be found in ships, vehicles, aircraft, barracks, and bases. While it helped protect equipment, it also exposed countless service members to asbestos, a dangerous substance known to cause serious diseases such as mesothelioma, lung cancer, and asbestosis.

Why are veterans at a higher risk?

The military relied heavily on asbestos as a durable, inexpensive, and fire-resistant material. As a result, veterans from nearly every branch (Navy, Army, Marine Corps, Air Force, and Coast Guard) may have been exposed during their service. Navy veterans are among the most frequently affected because of the extensive use of asbestos on ships.

According to the U.S. Department of Veterans Affairs (VA), asbestos exposure was especially common among those who worked in:

Shipyards and naval vessels – where asbestos insulated pipes, boilers, and engines
Aircraft maintenance – involving gaskets, valves, and insulation materials
Vehicle repair – especially when replacing brakes or clutches
Construction and carpentry – including roofing, flooring, and cement work
Power plants and mechanical rooms – with turbines and other heat-generating machinery

Long-term health effects

Asbestos-related diseases often take decades to appear after exposure. Many veterans who were exposed in the 1960s, 70s, or 80s are only now being diagnosed. When asbestos fibers are inhaled or swallowed, they can lodge in the lining of the lungs, abdomen, or heart, leading to inflammation and, over time, serious illness.

Common conditions linked to asbestos exposure include:

Mesothelioma: a rare and aggressive cancer of the lining of the lungs or abdomen
Lung cancer: which can develop even in those who never smoked
Asbestosis: a chronic lung disease that causes scarring on lung tissue and breathing difficulties

Symptoms often appear gradually and can include shortness of breath, chest or abdominal pain, fatigue, or unexplained weight loss. Veterans who notice these symptoms should tell their healthcare providers about any possible asbestos exposure during their service.

Support and Resources for Veterans

Veterans diagnosed with asbestos-related diseases may be eligible for VA health care and disability benefits. These benefits recognize the connection between military service and asbestos exposure and can help cover treatment and related expenses.

In addition to VA benefits, veterans and their families can turn to a range of organizations and support networks that focus on asbestos-related illnesses. These groups provide education, emotional support, and guidance for navigating complex medical and benefit systems.

Raising Awareness

Every veteran deserves to understand the risks they faced in service and to receive care if those risks led to illness. Sharing information about asbestos exposure helps others recognize symptoms earlier and seek proper medical attention.

If you or a loved one served in the military and have been diagnosed with mesothelioma or another asbestos-related disease, you are not alone. Learning about the connection between asbestos and military service is the first step toward getting help, treatment, and support.

International Symposium on Malignant Mesothelioma Brings Together Patients and Clinicians in Philadelphia

The annual International Symposium on Malignant Mesothelioma, hosted by the Mesothelioma Applied Research Foundation, brought together leading researchers, clinicians, patients, and advocates in Philadelphia this weekend for two days of groundbreaking discussion, collaboration, and support centered on advancing mesothelioma research and care.

Legal_panel

Symposium

pleural_tumor_board

MESOTHELIOMA TREATMENT AND SCIENCE

For pleural mesothelioma patients, the Pleural Tumor Board Panel provided information about available treatment options but also covered the rationale employed by multidisciplinary teams when deciding the best course of action for a patient. Experts on the panel included:

Melina Marmarelis, MD, University of Pennsylvania (Medical Oncologist)
Adam Bograd, MD, Swedish Cancer Institute (Thoracic Surgeon)
Mehmet Altan, MD, MD Anderson Cancer Center (Medical Oncologist)
Michael Offin, MD, Memorial Sloan Cancer Center (Medical Oncologist)

The panel walked attendees through two real cases, illustrating how multidisciplinary teams make complex decisions about personalized treatment plans. In mesothelioma there are few approved treatments available, and their efficacy largely depends on the cellular and molecular features of the tumor, so some disagreement in approach is to be expected. Overall, the experts agreed with front line therapy of immunotherapy for non-immune compromised patients and chemotherapy for those not eligible for immunotherapy. Surgery (pleurectomy decortication) can be considered as a treatment option in certain circumstances, namely an epitheliod cell type, and when the patient is fit enough to withstand the stress and recovery of such an intricate operation. Treatment before surgery (known as neoadjuvant treatment) and treatment after surgery (known as adjuvant treatment) with the same chemotherapy and immunotherapy agents is typically recommended. For sarcomatoid patients, immunotherapy is the best option, and those patients are generally not surgical candidates. Surgery can also be an effective tool for palliation of pain and difficulty breathing.

For peritoneal mesothelioma patients, the Peritoneal Tumor Board Panel was structured to provide treatment information and an understanding of rationale for those treatments. That panel included:

Jason Foster, MD, University of Nebraska (Peritoneal Mesothelioma Surgeon)
Hedy Kindler, MD, University of Chicago Medicine (Medical Oncologist)
Michael Offin, MD, Memorial Sloan Kettering Cancer Center (Medical Oncologist)
Georgios Karagkounis, MD, Memorial Sloan Kettering Cancer Center (Peritoneal Mesothelioma Surgeon)

Unlike pleural mesothelioma, peritoneal mesothelioma does not have a set standard treatment outlined and agreed upon by experts nor is there a staging system that would standardize the results. However, it is generally accepted as best practice to perform cytoreductive surgery followed by HIPEC (hyperthermic intraperitoneal chemotherapy). Additionally, systemic chemotherapy and immunotherapy are also available to these patients.

WHAT’S NEW WITH CLINICAL TRIALS AND TARGETED THERAPIES

Beyond treatment updates, the symposium also highlighted advances in imaging and clinical trials shaping the future of mesothelioma care.

Dean Fennell, MD, PhD, University of Leicester (Medical Oncologist) provided an overview of emerging and recently completed clinical trials. Beyond large, systemic treatment studies, mesothelioma patients have the option of enrolling in several targeted treatment clinical trials, eligibility for which depends on the molecular features of their tumors.

THE ROLE OF AI IN MEDICAL IMAGING

As the world adjusts to the sudden advent of artificial intelligence (AI), the medical field has already been working to galvanize the benefits of machine learning in area where consistency is paramount. Medical imaging is one of those areas. The presentation by Kevin Blyth, MD, University of Glasgow looked at new ways in which AI can assist doctors by enhancing accuracy of interpretation in imaging interpretation.

SUPPORT, ADVOCACY, AND LEGAL INSIGHT

Social interaction and support groups are a big part of this conference, providing attendees the ability to connect with others who have undergone similar challenges. Patients and their families had numerous opportunities to interact and share information informally, but other non-medical panels also helped with that.

Legal Panel: this session featured Seth Dymond, Esq., a partner attorney with Belluck Law, LLP who participated in a rapid-fire Q&A and provided additional clarification on legal issues as they relate to asbestos and mesothelioma litigation.
Clinical Trials Patient Panel: unlike the sessions featuring medical professionals, this session put forth patients who participated in clinical trials to share their experiences with enrollment and their ability to tolerate treatment and side effects.
Survivorship Patient Panel: panelists discussed their experience after treatment as they related to physical and mental health

The symposium closed with a sense of optimism, solidarity, and newly acquired friendships underscoring the Foundation’s mission to connect science, care, and community. Recordings of additional sessions are available on the Mesothelioma Applied Research Foundation’s website and YouTube channel.

SPONSORSHIPS

Belluck Law, LLP was one of the top sponsors of the conference. Belluck Law, LLP, is a premier national firm specializing in mesothelioma and asbestos cases. With offices in New York City and across the state of New York in Albany, Rochester, Woodstock, Gloversville and offices in Maine, Massachusetts, and New Jersey. The firm has recovered over $1 billion in compensation on behalf of its clients. The firm’s attorneys have been recognized by Best Lawyers, Best Law Firms, SuperLawyers, Martindale Hubbell and other peer and third-party attorney evaluators.

In September of 2025, the firm obtained an $83 million verdict on behalf of a client exposed to asbestos by working with clay, and in earlier in the same month, the firm obtained a nearly $12.25 million verdict on behalf of another client who was exposed to asbestos by living near a talc mine.

Category: Featured News